2025年全球生物技术行业调查报告：不确定性如何塑造生物技术雄心

Core Viewpoint - The biotechnology industry is at a crossroads, with a paradox of rising internal confidence despite external uncertainties, leading to a historical shift in treatment areas and global innovation landscape [2]. Group 1: Financing Environment - The financing environment for the biotechnology industry has shifted from enthusiasm to a rational panic, with 92% of investors expressing confidence in achieving the next investment milestone, despite a significant increase in companies seeking additional R&D funding from 14% in 2023 to 41% in 2025 [3]. - The capital allocation logic is fundamentally changing, with venture capital moving from a "broad net" strategy to "mega bets," resulting in a stark resource polarization where leading companies receive ample funding while many small and medium-sized biotech firms face liquidity crises [3][4]. Group 2: Treatment Landscape Changes - Neuroscience has emerged as the leading research focus in biotechnology, surpassing oncology for the first time, with an active rate of 44% compared to oncology's 30%, indicating a systemic shift in industry risks and technological breakthroughs [5]. - The marginal returns on oncology drug development are decreasing due to intense competition in popular targets, while breakthroughs in neuroscience related to diseases like Alzheimer's are reigniting industry ambitions [5]. Group 3: Technological Modalities - Cell therapy has become the most active technological modality at 40%, while small molecule drugs account for 28%, indicating a shift towards more complex biotechnological innovations [6]. Group 4: China's Role in Biotechnology - China is solidifying its position as a "biotechnology superpower," ranking in the top ten of the global innovation index and matching the U.S. in clinical trial numbers, presenting significant opportunities for venture capital and multinational pharmaceutical companies [7][8]. - However, the rise of China's biotechnology sector is viewed as a strategic challenge by Western governments, leading to increased regulatory scrutiny and geopolitical tensions [8]. Group 5: Talent and AI in Drug Development - The complexity of drug development and talent acquisition remains a significant concern, with talent demand in the Asia-Pacific region being three times higher than in Europe and the U.S. due to rapid industry growth [9]. - The biotechnology industry is increasingly turning to artificial intelligence (AI) and digital tools to enhance R&D efficiency, with 76% of stakeholders expecting AI to accelerate their development processes in the next two years [10].